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Key Clinical Message
Our results prove that c.1871-14T>G is causative of type I PS deficiency, high-
lighting the importance of performing mRNA-based studies in order to evaluate
variants pathogenicity. We evidence the increased risk of venous thromboem-
bolism associated with this cryptic splice-site variant if present in patients with
PS deficiency.
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Introduction
Protein S (PS) is a widely studied protein with an important
function in the downregulation of thrombin formation.
Since its discovery in 1976, more than 400 variants have
been described in PS gene (PROS1) associated with PS defi-
ciency and as a risk factor for venous thromboembolism
(VTE). We describe a novel variant, c.1871-14T>G, in intron
14 of PROS1 gene identified in two patients with PS defi-
ciency from two unrelated families with a history of throm-
botic disease. This alteration leads to a PROS1 mRNA
expression reduction, probably due to nonsense-mediated
mRNA decay. Our results suggest that c.1871-14T>G is cau-
sative of type I PS deficiency in these patients, highlighting
the importance of screening not only the coding and the
most conserved intron–exon junctions, but also perform
mRNA-based studies. We call attention to the potential
increased risk of VTE in hereditary type I PS deficiency asso-
ciated with this cryptic splice-site variant.
Report
Hereditary PS deficiency (PSD) is an autosomal dominant
disorder associated with an increased risk of venous
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thromboembolism (VTE) [1, 2]. The genetic basis of PSD
is heterogeneous and is also associated with phenotypic
variability. More than 400 variants in PROS1 have been
described, the vast majority being missense or nonsense
variants, distributed along the coding region [3]. In this
report, we describe a novel c.1871-14T>G variant in PROS1
intron 14, identified in two patients from two unrelated
families, both with PSD and history of thrombotic disease.
Two unrelated Portuguese women were referred for
genetic analysis of the PROS1 gene due to PSD and clini-
cal conditions associated with thromboembolism (Fig. 1A,
probands F1-III2 and F2-IV3). Plasma levels of total
(TPS) and free protein S (FPS) antigen were below the
lower limit of reference, suggesting type I PSD. After
obtained informed consent, peripheral blood (PB) sam-
ples were collected for PROS1 molecular analysis of
patients F1-III2 and F2-IV3. PB was also available from
patient F1-III2 for mRNA studies, and from her mother
and sister for PROS1, c.20210G>A Prothrombin and Fac-
tor V Leiden genetic testing.
As there were no other factors that could potentially
result in a decrease in PS levels in patients F1-III2 and
F2-IV3, hereditary type I PSD was suspected (Fig. 1A).
Standard molecular analysis of PROS1 [4] culminated
with the identification of a T>G transversion at position-
14 of the acceptor splice site of intron 14 in patients
F1-III2 and F2-IV3. This alteration was not identified in
the mother of F1-III2 (Fig. 1B), suggesting that it is of
paternal origin. To our knowledge, the PROS1 c.1871-
14T>G variant was not described associated with PSD
and it is very rare in the general population
(rs754929347; MAF C = 0.000009/1). Analysis of this
variant using the Alamut-v2.2 interactive biosoftware pre-
dicted the creation of a new cryptic acceptor splice site
(scores: SSF = 71.78; MaxEnt = 2.32 and HSF = 76.10).
As c.1871-14T>G has a potential effect on intron 14–
exon 15 acceptor splice site, we decided to study its
PROS1 mRNA. For this purpose, RNA was isolated from
fresh PB leukocytes (obtained from patient F1-III2) and
cDNA was amplified. As a result, two PCR products of
150-bp and 163-bp in the patient cDNA were amplified,
unlike the healthy control sample in which only the wild-
type (wt) allele of 150-bp was obtained, as expected
(Fig. 1C). To better characterize the 150-bp and 163-bp
fragments, both were separately cloned and sequenced.
We found, as expected, that the 150-bp fragment from
the patient and the control sample corresponds to the wt
allele with the correct junction of exons 14 and 15 (data
not shown). However, the 163-bp fragment retained the
last 13 nucleotides (nt) of intron 14 (Fig. 1D). In order
to quantitatively evaluate the expression level of wt
PROS1 mRNA in proband F1-III2, we performed real-
time PCR using specific primers for the wt allele
(Fig. 1E). Our results demonstrated that the patient F1-
III2 sample has only 40% of total wt PROS1 mRNA when
compared to the healthy control (P = 0.035).
Finally, we decided to investigate how the retention of
these 13 nt in the mRNA of PROS1 would affect the
PROS1 protein. In silico analysis using the ExPASy trans-
late tool revealed that the additional 13 nt of the mutant
allele, alters the reading frame, predicting a truncated
protein that loses all amino acids encoded by exon 15
(green sequence) and creates a premature termination
codon (PTC) 17 amino acids downstream (red sequence)
(Fig. 1F). However, nonsense-mediated mRNA decay
(NMD) may recognize and selectively degrades this
mRNA carrying PTC, preventing the production of a
truncated protein.
To date, only few studies have experimentally demon-
strated the functional consequences of PROS1 variants
associated with type I PSD. Variants in PROS1 leading to
deleterious alleles, such as frameshift or splice-site vari-
ants, result in significant sequence alterations and often
introduce PTCs, as was demonstrated with this study. In
Figure 1. (A) Pedigrees from probands F1-III2 and F2-IV3. The arrow indicates each proband. Relevant results are below each family member:
FPS, TPS, FcPS—free, total, and functional protein S, respectively. CVT, cerebral venous thrombosis; AMI, acute myocardial infarction. *Clinical
diagnosis and laboratory analysis performed elsewhere. Orange and blue—stand for PS deficiency and FV Leiden heterozygosity, respectively.
Heterozygosity (hetz) for PROS1 variant c.1871-14T>G and the clinical condition are shadowed in gray. (B) DNA sequence results of PROS1 intron
14–exon 15 junctions of F1-III2, F1-II4, and F2-IV3. Molecular analysis revealed that F1-III2 and F2-IV3 are heterozygous for PROS1: c.1871-14T>G
variant (NCBI sequence reference: NM_000313.3) that is predicted to activate new intronic cryptic acceptor splice site. (C) PROS1 transcript
amplification analysis of exon 14–exon 15 junctions in a 2% agarose gel. The 150-bp fragment in the control (C) and F1-III2 results from the
amplification of the wild-type (wt) allele, and the 163-bp fragment found in F1-III2 is from amplification of the mutant allele. The 70-bp fragment
in the C and F1-III2 corresponds to GAPDH (internal control) amplification. M: NZYDNA ladder VI; B: Mock. (D) Chromatogram of the 163-bp RT-
PCR fragment from patient F1-III2. The sequence analysis revealed that c.1871-14T>G variant resulted in the retention of the last 13 nucleotides
from intron 14, inserted between exons 14 and 15 in PROS1 mRNA. (E) Quantification of wt PROS1 mRNA expression by real-time PCR from
patient F1-III2. The expression levels of PROS1 mRNA were normalized to the internal control GAPDH mRNA. The values of PROS1 mRNA
amplicons from F1-III2 were compared to the control sample, arbitrarily set to 1. Patient F1-III2 produces 40% of total wt PROS1 mRNA when
compared to a healthy control (P = 0.035). (F) In silico prediction of c.1871-14G>T variant in the PROS1 protein sequence. The insertion in the
mutant allele alters the reading frame and predicting a truncated protein that loses all amino acids encoded by exon 15 and gains a premature
stop codon.
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addition, in silico splice-site prediction tools are not
enough to take definitive conclusions about the variants
functional consequences. Additional mRNA-based studies
should be performed when putative splicing variants are
identified. To elucidate the genetic causes underlying PSD
and the heterogeneity observed in its phenotypic manifes-
tation, it is essential to investigate the consequences of
naturally occurring PROS1 variants. Our results shed
some light on the mechanism by which splice-site variants
can alter plasma PS levels.
Concerning the risk of VTE, both patients have PS
levels below the lower limit of the reference range. This
splicing variant probably results in a reduced synthesis of
PS reflected in lower levels of FPS and TPS identified in
the affected members of these two families, and possibly
they have a putative increased risk of VTE as was
reported in previous studies [2, 5]. We also emphasize
the occurrence of a thrombotic episode at an early age
(26 years) in patient F1-III1, which probably is related to
the cumulative effect of the cosegregation of PROS1:
c.1871-14T>G and FV Leiden, another well-known risk
factor for thrombosis, demonstrating that the risk of
thrombosis is higher in carriers of double defects.
In conclusion, we describe a novel c.1871-14T>G
splice-site variant probably causative of type I PSD and
supports the importance of the molecular and functional
characterization of naturally occurring PROS1 variants,
such as mRNA-based studies in the cases of putative
splice-site variants.
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